Ballentine Partners’s Amicus Therapeutics FOLD Stock Holding History

Ballentine Partners’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,620	Closed	-$197K	–	1096
2026 Q1	$197K	Hold	13,620	–	–	﹤0.01%	944
2025 Q4	$194K	Sell	13,620 -270	-2%	-$2.65K	﹤0.01%	931
2025 Q3	$109K	Buy	+13,890	New	+$98.9K	﹤0.01%	972

Ballentine Partners's FOLD Position: Q2 2026 in Review

Ballentine Partners sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 13,620 shares — an estimated $197K sold.

Ballentine Partners first reported a position in FOLD in Q3 2025 and held it in 3 quarters. The position peaked at $197K in Q1 2026. 0 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Ballentine Partners reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Ballentine Partners sold 13,620 Amicus Therapeutics shares in Q2 2026, an estimated $197K.
Ballentine Partners first reported a position in Amicus Therapeutics in Q3 2025 and held it in 3 quarters.
Ballentine Partners's Amicus Therapeutics position peaked at $197K in Q1 2026.
0 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.